UNSPSC 51421901: Naflocort

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B52439Y33, chemically known as 9-fluoro-1,4-dihydro-11beta,21-dihydroxy-2betah-naphtho(2,3:16,17)pregna-1,4-diene-3,20-dione but generally known as naflocort, which bears US NIH Compound Identifier 64767. European Medicines Agency schedules Naflocort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09124MIG.

UNSPSC 51421901 Naflocort is a Commodity code nominally covering a specific pharmaceutical product, but the recent state and local opportunities posted under it do not align with that scope. Seminole County, Florida issued IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to its Community Health Building in Sanford, Florida; the Texas Health and Human Services Commission issued RFI HHS0017013 to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative for direct-to-manufacturer prescription fulfillment. Neither solicitation targets naflocort specifically, and the code shows a mismatch between its nominal pharmaceutical designation and the actual procurement activity being tagged to it in state and local systems.

The Seminole County opportunity represents the more concrete buying signal, with a fixed two-year initial term plus a one-year renewal option, electronic bid submission required through the county's e-Procurement Portal, and a response deadline of July 26, 2023 at 2:00 pm; vendors must provide unit costs for each line item, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation and commercial general liability insurance. The Texas RFI remains preliminary intelligence-gathering, with responses due April 3, 2026, seeking vendor experience in direct contracting with self-insured employers and health plans using negotiated net pricing models outside traditional pharmacy benefit manager and group purchasing organization channels. Activity under this code spans Florida and Texas; the mismatch between the code's nominal scope and actual recent solicitations signals either tagging error or a broader pharmaceutical procurement grouping in state and local taxonomies. Practitioners should verify issuing-agency coding before pursuit.